Global Non-Small Cell Lung Cancer (NSCLC) Market:- Market Size, Share, Competition, Industry Trends and Opportunity Analysis and Forecast to 2028
- OI-237 |
- Published date: May, 2021 |
- Non-small cell lung cancer |
- Pages
The global Non-Small Cell Lung Cancer (NSCLC) Markett was valued at approximately $XX billion in 2020 and is projected to register XX% CAGR over the forecast period.
•Uncontrolled cell growth in lungs leads to lung cancer. The disease can progress to other body parts. There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). According to Lung Cancer Alliance, a nonprofit organization focused on prevention and treatment of lung cancer states that out of overall lung cancer, around 80 to 85% cases found are of NSCLC and 15-20% cases found are of SCLC.
•Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need remains a key area of focus for drug developers.
•The treatment for NSCLC is becoming increasingly fragmented as more biomarker-driven therapies enter the market. However, owing to the limited size of these patient subpopulations, the immune checkpoint inhibitors, most notably Keytruda (Merck & Co.), continue to dominate the NSCLC market.
•Competition is set to intensify further over the forecast period as multiple immune checkpoint inhibitor-based combination therapies gain approval and enter clinical practice.
•In addition, a flurry of novel agents and regimens from different drug classes are in development for NSCLC, including ALK, MET, and RET inhibitors, immune checkpoint inhibitors, angiogenesis inhibitors, and therapeutic vaccines, all striving for a share of the increasingly crowded and competitive market.
The global Non-Small Cell Lung Cancer (NSCLC) Markett was valued at approximately $XX billion in 2020 and is projected to register XX% CAGR over the forecast period.
•Uncontrolled cell growth in lungs leads to lung cancer. The disease can progress to other body parts. There are two main types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). According to Lung Cancer Alliance, a nonprofit organization focused on prevention and treatment of lung cancer states that out of overall lung cancer, around 80 to 85% cases found are of NSCLC and 15-20% cases found are of SCLC.
•Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need remains a key area of focus for drug developers.
•The treatment for NSCLC is becoming increasingly fragmented as more biomarker-driven therapies enter the market. However, owing to the limited size of these patient subpopulations, the immune checkpoint inhibitors, most notably Keytruda (Merck & Co.), continue to dominate the NSCLC market.
•Competition is set to intensify further over the forecast period as multiple immune checkpoint inhibitor-based combination therapies gain approval and enter clinical practice.
•In addition, a flurry of novel agents and regimens from different drug classes are in development for NSCLC, including ALK, MET, and RET inhibitors, immune checkpoint inhibitors, angiogenesis inhibitors, and therapeutic vaccines, all striving for a share of the increasingly crowded and competitive market.
